Anuja Dokras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anuja Dokras has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
- Laura G. Cooney
Department of Obstetrics and Gynecology, University of Wisconsin, Madison, Wisconsin
7 shared publications Kelly C. Allison
Department of Psychology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
6 shared publicationsMary D. Sammel
Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, Pennsylvania
6 shared publications- Helena Jane Teede
Monash Centre for Health Research and Implementation, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia
5 shared publications Christos Coutifaris
Affiliation Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
4 shared publications- Iris Tien-Lynn Lee
Department of Obstetrics and Gynecology, University of Pennsylvania , Philadelphia, PA 19104
4 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by World Scientific Pub Co Pte Ltd in Fertility & Reproduction
- Vol. 08 (03) , 97-101
Mental Health in Polyendocrine Metabolic Ovarian Syndrome (PMOS): Prevalence, Aetiology and Management Across the Lifespan
Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), affects approximately 8%–13% of reproductive-aged women worldwide and is one of the most common endocrine disorders in women. Psychiatric comorbidities represent a substantial but often underrecognised component of this multisystem condition. This narrative review summarises current evidence on the prevalence, mechanisms and management of psychiatric disorders in PMOS across the lifespan. Women with PMOS have significantly higher rates of depression, anxiety, eating disorders, ADHD, bipolar disorder and OCD than women without PMOS. Reduced quality of life, body image distress and emerging evidence of increased suicidal ideation further contribute to the disease burden. Psychiatric morbidity persists beyond the reproductive years and appears to be amplified by obesity and metabolic dysfunction. Proposed mechanisms include hyperandrogenism, insulin resistance, neuroinflammation, hypothalamic–pituitary–adrenal axis dysregulation, sleep disturbance and psychosocial stressors. Evidence-based management includes routine screening, psychological interventions, pharmacotherapy when indicated, lifestyle modification and coordinated endocrine, metabolic and mental health care. Psychiatric comorbidity is a core clinical feature of PMOS and warrants routine screening, longitudinal surveillance and integrated management across the lifespan.
- 22 September 2026
- Published by World Scientific Pub Co Pte Ltd in Fertility & Reproduction
- Vol. 08 (03) , 97-101
Open AccessMental Health in Polyendocrine Metabolic Ovarian Syndrome (PMOS): Prevalence, Aetiology and Management Across the Lifespan
Polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), affects approximately 8%–13% of reproductive-aged women worldwide and is one of the most common endocrine disorders in women. Psychiatric comorbidities represent a substantial but often underrecognised component of this multisystem condition. This narrative review summarises current evidence on the prevalence, mechanisms and management of psychiatric disorders in PMOS across the lifespan. Women with PMOS have significantly higher rates of depression, anxiety, eating disorders, ADHD, bipolar disorder and OCD than women without PMOS. Reduced quality of life, body image distress and emerging evidence of increased suicidal ideation further contribute to the disease burden. Psychiatric morbidity persists beyond the reproductive years and appears to be amplified by obesity and metabolic dysfunction. Proposed mechanisms include hyperandrogenism, insulin resistance, neuroinflammation, hypothalamic–pituitary–adrenal axis dysregulation, sleep disturbance and psychosocial stressors. Evidence-based management includes routine screening, psychological interventions, pharmacotherapy when indicated, lifestyle modification and coordinated endocrine, metabolic and mental health care. Psychiatric comorbidity is a core clinical feature of PMOS and warrants routine screening, longitudinal surveillance and integrated management across the lifespan.
- Open Access
- 2 September 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (5) , 767-768
Polyendocrine metabolic ovarian syndrome comes of age: from genetic risk to lifelong care
- 2 September 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 126 (5) , 767-768
Open AccessPolyendocrine metabolic ovarian syndrome comes of age: from genetic risk to lifelong care
- Open Access
- 28 August 2026
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 235 (5) , 999-1002
From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: what obstetricians and gynecologists need to know
- 28 August 2026
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 235 (5) , 999-1002
Open AccessFrom polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: what obstetricians and gynecologists need to know
- Open Access
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
11-Oxygenated androgens in PCOS: impact of PCOS phenotypes and first-line interventions
Context: Androgen excess in polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) is classically attributed to ovarian steroids, yet adrenal-derived 11-oxygenated androgens are potent contributors whose regulation and treatment responsiveness in PMOS remains poorly characterized. Objective: To quantify classic and 11-oxygenated androgens across PMOS phenotypes vs controls and to evaluate their responses to oral contraceptive pills (OCPs), metformin, or lifestyle modification (LSM). Design: Secondary analysis of residual serum samples from 3 trials: oral contraceptives versus weight loss (OWL)–PCOS trial (16-week OCP vs LSM), combined OCPs versus metformin (COMET)–PCOS trial (24-week OCP vs metformin), and assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial (controls). Setting: Two academic medical centers. Patients or Other Participants: Two hundred and seventy-six with Rotterdam-defined PMOS and 97 controls. Intervention(s): Low-dose OCPs (4-6 months), metformin (2000 mg/day for 6 months), or LSM (4 months). Main Outcome Measure(s): Serum concentrations of 11β-hydroxytestosterone (11-OHT), 11-ketotestosterone (11-KT), 11-ketoandrostenedione (11-KA4), and 11β-hydroxyandrostenedione (11-OHA4) measured by liquid chromatography–tandem mass spectrometry, and total testosterone (TT), at baseline and end of study. Results: Adjusting for age and body mass index, women with PCOS/PMOS had higher median 11-OHT (11.0 vs 7.8 ng/dL; P = .01) and 11-KT (31.9 vs 25.6 ng/dL; P = .03) than controls. Elevations were phenotype specific: biochemical hyperandrogenism showed broad increases, whereas clinical hyperandrogenism with normal TT found no significant differences compared with controls. Oral contraceptive pills suppressed 11-KT, 11-KA4, and 11-OHT (all P < .001), comparable to TT reductions. Metformin produced modest reductions in 11-OHT and 11-KT (P < .05), while LSM had no effect. Changes were independent of body mass index, glycemia, and homeostatic model assessment for insulin resistance (HOMA-IR). Conclusion: 11-Oxygenated androgens are elevated in PMOS in a phenotype-specific manner and are strongly suppressed by OCPs, with modest response to metformin and no short-term effect from LSM, supporting their utility in phenotyping and treatment monitoring.
- 13 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open Access11-Oxygenated androgens in PCOS: impact of PCOS phenotypes and first-line interventions
Context: Androgen excess in polycystic ovary syndrome (PCOS)/polyendocrine metabolic ovarian syndrome (PMOS) is classically attributed to ovarian steroids, yet adrenal-derived 11-oxygenated androgens are potent contributors whose regulation and treatment responsiveness in PMOS remains poorly characterized. Objective: To quantify classic and 11-oxygenated androgens across PMOS phenotypes vs controls and to evaluate their responses to oral contraceptive pills (OCPs), metformin, or lifestyle modification (LSM). Design: Secondary analysis of residual serum samples from 3 trials: oral contraceptives versus weight loss (OWL)–PCOS trial (16-week OCP vs LSM), combined OCPs versus metformin (COMET)–PCOS trial (24-week OCP vs metformin), and assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial (controls). Setting: Two academic medical centers. Patients or Other Participants: Two hundred and seventy-six with Rotterdam-defined PMOS and 97 controls. Intervention(s): Low-dose OCPs (4-6 months), metformin (2000 mg/day for 6 months), or LSM (4 months). Main Outcome Measure(s): Serum concentrations of 11β-hydroxytestosterone (11-OHT), 11-ketotestosterone (11-KT), 11-ketoandrostenedione (11-KA4), and 11β-hydroxyandrostenedione (11-OHA4) measured by liquid chromatography–tandem mass spectrometry, and total testosterone (TT), at baseline and end of study. Results: Adjusting for age and body mass index, women with PCOS/PMOS had higher median 11-OHT (11.0 vs 7.8 ng/dL; P = .01) and 11-KT (31.9 vs 25.6 ng/dL; P = .03) than controls. Elevations were phenotype specific: biochemical hyperandrogenism showed broad increases, whereas clinical hyperandrogenism with normal TT found no significant differences compared with controls. Oral contraceptive pills suppressed 11-KT, 11-KA4, and 11-OHT (all P < .001), comparable to TT reductions. Metformin produced modest reductions in 11-OHT and 11-KT (P < .05), while LSM had no effect. Changes were independent of body mass index, glycemia, and homeostatic model assessment for insulin resistance (HOMA-IR). Conclusion: 11-Oxygenated androgens are elevated in PMOS in a phenotype-specific manner and are strongly suppressed by OCPs, with modest response to metformin and no short-term effect from LSM, supporting their utility in phenotyping and treatment monitoring.
- Top Cited Papers
- 22 May 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 1956-1957
Naming in medicine: how disease nomenclature shapes diagnosis, research and patient lives
- 22 May 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 1956-1957
Top Cited PapersNaming in medicine: how disease nomenclature shapes diagnosis, research and patient lives
- 27 February 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 125 (5) , 784-785
Don’t let hype outrun evidence: why preimplantation genetic testing for polygenic disease risk shouldn’t be rushed into clinics
- 27 February 2026
- Published by Elsevier in Fertility and Sterility
- Vol. 125 (5) , 784-785
Don’t let hype outrun evidence: why preimplantation genetic testing for polygenic disease risk shouldn’t be rushed into clinics
- Open Access
- 8 December 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (12) , e1004662
Impact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial
Background: The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS. Methods and findings: We conducted a multicenter, double-blind, double-dummy, randomized trial (COMET-PCOS) in participants between ages ≥18 and ≤40 years and body mass index (BMI) ≥25 kg/m 2 and ≤ 48 kg/m 2 with hyperandrogenic PCOS (defined by the Rotterdam criteria). Participants were randomized 1:1:1 to 24 weeks of low-dose COCPs (20 μg ethinyl estradiol/0.15 mg desogestrol), metforminXR (2,000 mg), or both (Combined). The primary outcome, assessed by intention-to-treat analysis, was the effect of the different treatment groups on the prevalence of MetS at the end of study. The analytical model included site, race, and the presence or absence of MetS at the screening visit as covariates. The secondary outcomes included changes in each component of MetS (TG, HDL-C, BP, WC, and fasting glucose levels) over the study period. Of the 240 participants randomly assigned, 20 out of 79 in the COCP group, 16 out of 81 in the metformin group, and 17 out of 80 in the combined group dropped out of the study. A total of 169 participants (70.4%) completed the trial between January 2018 and June 2023 (mean age: 29.5 years; mean BMI: 35.6 kg/m 2 ; 70% were White and 23% were Black). The overall prevalence of MetS was 31% at baseline and comparable across groups. At the end of the study, the prevalence of MetS was 26.2% (17/65) in the metformin group, 28.6% (17/59) in the Combined group, and 28.8% (17/59) in COCP group with no significant difference in trend of MetS prevalence between groups (adjusted p = 0.26). Waist circumference (mean change (MC) −2.23 cm; 95% CI [−3.98, −0.49]; p = 0.01), BMI (MC −0.49 kg/m 2 ; 95% CI [−0.88, −0.10]; p = 0.01), and android fat mass measured by DXA (MC −167 g; 95% CI [−264, −71[; p < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. In the metformin and Combined groups, the majority of participants (>64%) reported diarrhea, while 24.1% in the COCP group reported uterine bleeding. The main methodologic limitation of the study is the potential lack of power to detect differences in secondary outcomes. Conclusions: In participants with hyperandrogenic PCOS and overweight/obesity, low-dose COCPs effectively managed PCOS symptoms without increasing prevalence of MetS. Our findings challenge the current practice of using metformin alone or with COCPs for lowering cardiometabolic risk. Trial registration: ClinicalTrials.Gov Identifier: NCT03229057.
- 8 December 2025
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 22 (12) , e1004662
Open AccessImpact of combined hormonal contraceptives and metformin on metabolic syndrome in women with hyperandrogenic polycystic ovary syndrome and obesity: The COMET-PCOS randomized clinical trial
Background: The risk-to-benefit ratio of using combined oral contraceptive pills (COCPs) and/or metformin for comprehensive management of polycystic ovary syndrome (PCOS) in women with obesity is unclear. As there is a lack of robust evidence on the impact of these first-line medications on cardiovascular disease (CVD) risk, we compared the effect of COCPs, metformin or both on prevalence of metabolic syndrome (MetS) in participants with hyperandrogenic PCOS and hypothesized that COCPs would increase prevalence of MetS while metformin would decrease prevalence of MetS. Methods and findings: We conducted a multicenter, double-blind, double-dummy, randomized trial (COMET-PCOS) in participants between ages ≥18 and ≤40 years and body mass index (BMI) ≥25 kg/m 2 and ≤ 48 kg/m 2 with hyperandrogenic PCOS (defined by the Rotterdam criteria). Participants were randomized 1:1:1 to 24 weeks of low-dose COCPs (20 μg ethinyl estradiol/0.15 mg desogestrol), metforminXR (2,000 mg), or both (Combined). The primary outcome, assessed by intention-to-treat analysis, was the effect of the different treatment groups on the prevalence of MetS at the end of study. The analytical model included site, race, and the presence or absence of MetS at the screening visit as covariates. The secondary outcomes included changes in each component of MetS (TG, HDL-C, BP, WC, and fasting glucose levels) over the study period. Of the 240 participants randomly assigned, 20 out of 79 in the COCP group, 16 out of 81 in the metformin group, and 17 out of 80 in the combined group dropped out of the study. A total of 169 participants (70.4%) completed the trial between January 2018 and June 2023 (mean age: 29.5 years; mean BMI: 35.6 kg/m 2 ; 70% were White and 23% were Black). The overall prevalence of MetS was 31% at baseline and comparable across groups. At the end of the study, the prevalence of MetS was 26.2% (17/65) in the metformin group, 28.6% (17/59) in the Combined group, and 28.8% (17/59) in COCP group with no significant difference in trend of MetS prevalence between groups (adjusted p = 0.26). Waist circumference (mean change (MC) −2.23 cm; 95% CI [−3.98, −0.49]; p = 0.01), BMI (MC −0.49 kg/m 2 ; 95% CI [−0.88, −0.10]; p = 0.01), and android fat mass measured by DXA (MC −167 g; 95% CI [−264, −71[; p < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. In the metformin and Combined groups, the majority of participants (>64%) reported diarrhea, while 24.1% in the COCP group reported uterine bleeding. The main methodologic limitation of the study is the potential lack of power to detect differences in secondary outcomes. Conclusions: In participants with hyperandrogenic PCOS and overweight/obesity, low-dose COCPs effectively managed PCOS symptoms without increasing prevalence of MetS. Our findings challenge the current practice of using metformin alone or with COCPs for lowering cardiometabolic risk. Trial registration: ClinicalTrials.Gov Identifier: NCT03229057.
- Top Cited PapersOpen Access
- 22 September 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (5) , 907-909
Polycystic ovary syndrome in 2025—insights and innovations
- 22 September 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (5) , 907-909
Top Cited PapersOpen AccessPolycystic ovary syndrome in 2025—insights and innovations
- Open Access
- 17 September 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (5) , 948-955
Neuropsychological profile of polycystic ovary syndrome: past, present, and future
- 17 September 2025
- Published by Elsevier in Fertility and Sterility
- Vol. 124 (5) , 948-955
Open AccessNeuropsychological profile of polycystic ovary syndrome: past, present, and future